Providence

Running trials

• Recruiting

  A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

  NCT07753993· Phase 3· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· Source

• Recruiting

  A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  NCT07221253· Phase 3· Source

• Recruiting

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· Phase 1/2· Source

• Recruiting

  Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

  NCT07181161· Phase 1/2· Source

• Recruiting

  A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

  NCT07192614· Phase 1/2· Source

• Recruiting

  Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  NCT07129993· Phase 2/3· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· Source

• Active, not recruiting

  Study for AZD4360 in Participants With Advanced Solid Tumours

  NCT06921928· Phase 1/2· Source

• Recruiting

  DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  NCT06989112· Phase 3· Source

• Recruiting

  A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

  NCT06564038· Phase 1/2· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· Source

• Recruiting

  AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  NCT06219941· Phase 2· Source

• Active, not recruiting

  A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

  NCT06188520· Phase 1/2· Source

• Recruiting

  A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

  NCT06103864· Phase 3· Source

• Active, not recruiting

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· Phase 3· Source

• Recruiting

  Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

  NCT05918861· Phase 3· Source

• Recruiting

  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  NCT05797168· Phase 1/2· Source

• Active, not recruiting

  First in Human Study of AZD9592 in Solid Tumors

  NCT05647122· Phase 1· Source

• Active, not recruiting

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· Phase 3· Source

• Active, not recruiting

  A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

  NCT05374512· Phase 3· Source

• Active, not recruiting

  Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

  NCT04421963· Phase 3· Source

• Active, not recruiting

  Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

  NCT04269200· Phase 3· Source

• Active, not recruiting

  COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

  NCT04068610· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

  NCT03530397· Phase 1· Source

• Active, not recruiting

  A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors

  NCT02671435· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer3 recruiting
• Endometrial cancer2 recruiting
• Gastric and esophageal cancer2 recruiting
• Liver and biliary tract cancer2 recruiting
• Lung cancer2 recruiting
• Chronic kidney disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Heart failure1 recruiting
• Mantle cell lymphoma1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

  NCT07529717· Phase 1/2· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Recruiting

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

  NCT06627647· Phase 3· Source

• Recruiting

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· Phase 3· Source

• Completed

  A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

  NCT05938270· Phase 1· Source

• Completed

  Tracking Treatment Pathways in Adult Patients With Hyperkalemia.

  NCT05408039· Source

• Completed

  A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

  NCT05432167· Phase 2· Source

• Terminated

  Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

  NCT04847232· Phase 3· Source